A medical oncologist shares their definition of CGP and how it plays a central role in routine cancer care. Their definition of CGP includes somatic testing to obtain sequencing data of clinically actionable genes for FDA-approved therapies or potential targetable alterations relevant to clinical trials. The stakeholder considers homologous recombination deficiency (HRD) as a must-have element of CGP in the next few years. They also discuss the importance of common variant types and tumor mutational burden. The stakeholder primarily focuses on treating patients with specific cancers and highlights the importance of CGP in guiding treatment decisions and improving patient outcomes. In terms of future changes, the stakeholder mentions the possibility of larger blood panels and increased reliance on blood-based testing, anticipating that blood testing could account for ~50% of CGP testing in the future. They also express the need for validated genomic signatures in more tumor types and the desire for faster turnaround times in CGP testing. Overall, the stakeholder recognizes the importance of CGP in guiding standard of care therapies and believes there are still unmet needs and opportunities for improvement in the field.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.